Evidence map›Paper›PMID 42057919›Full record

ArticleJournal of pathology informatics2026

Defining hotspot for estimation of Ki-67 proliferation index of neuroendocrine tumors: QuPath algorithm vs. manual assessment.

Ruben Oganesyan, Osman Yilmaz, Yevgen Chornenkyy, Kanchan Kantekure, Yuho Ono, Buthania Hakamy, Nandan Padmanabha, Vikram Deshpande, Raul S Gonzalez, Monika Vyas

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of pathology informatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ruben OganesyanBeth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
Osman YilmazEmory University Hospital, Atlanta, GA, USA.
Yevgen ChornenkyyBeth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
Kanchan KantekureBeth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
Yuho OnoBeth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
Buthania HakamyBeth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
Nandan PadmanabhaBeth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
Vikram DeshpandeBeth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
Raul S GonzalezEmory University Hospital, Atlanta, GA, USA.
Monika VyasBeth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Ki-67 proliferation index (PI) is essential for grading well-differentiated neuroendocrine tumors (WD-NETs). Pathologists traditionally assess Ki-67 PI by identifying hotspots and manually counting the positive cells among negative cells, which is expressed as a percentage. We developed an algorithm to objectively determine Ki-67 hotspots and calculate PI in WD-NETs, comparing its results with pathologists' selected hotspots to assess reliability. Methods: Hotspots for gastroenteropancreatic WD-NETs ( Results: Pathologists showed moderate agreement (Fleiss's Kappa = 0.42, 80% agreement), whereas pathologist-algorithm agreement was fair (Cohen's Kappa = 0.32, 58.9% agreement). Among cases with pathologist consensus grade ( Conclusion: Manual Ki-67 hotspot assessment is subjective, leading to grading variability. Algorithm-based assessment enhances reproducibility, though this occasionally leads to tumor upgrading, highlighting the need for standardization and further validation.

Indexed as

Computer assisted gradingKi-67QuPathWell-differentiated neuroendocrine tumors

Identifiers

PMID42057919
PMCPMC13121424

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.